IL-6 trans-signaling in a humanized mouse model of scleroderma

Ian D. Odell, Kriti Agrawal, Esen Sefik, A.v. Odell, Elizabeth Caves, Nancy C. Kirkiles-Smith, Valerie Horsley, Monique Hinchcliff, Jordan S. Pober, Yuval Kluger, Richard A. FlavellProceedings of the National Academy of Sciences 2023 · DOI

TL;DR

This study introduces a novel humanized mouse model (MISTRG6) that successfully recapitulates key aspects of scleroderma, a fibrotic autoimmune disease. By transplanting human skin and hematopoietic stem cells (HSCs), researchers found that healthy HSCs could mitigate fibrosis by downregulating IL-6 signaling, highlighting IL-6 trans-signaling as a critical driver of scleroderma pathogenesis.

What Problem Does This Paper Address?

Scleroderma, a complex autoimmune disease characterized by fibrosis of the skin and internal organs, poses a significant challenge for researchers due to the lack of fully humanized animal models. Understanding the intricate interplay between immune and mesenchymal cells in driving fibrosis has been hampered by the inability to accurately replicate human disease pathology in mice. Existing mouse models often fail to capture the full spectrum of human immune cell interactions and fibrotic processes. This paper aims to address this gap by developing and utilizing a humanized mouse model that can better mimic human scleroderma, enabling a deeper investigation into its underlying mechanisms.

Methods

The core of this research lies in the development and application of the MISTRG6 humanized mouse model. These mice are engineered to possess a human-like immune system through homologous gene replacement, allowing for the engraftment of human hematopoietic stem cells (HSCs). The study employed a two-pronged approach:

  • Skin Transplantation: Healthy and scleroderma patient-derived skin grafts (split-thickness skin grafts, STSG) were transplanted onto MISTRG6 mice.
  • HSC Engraftment: Mice were either engrafted with human HSCs or left unengrafted to compare the effects of human immune reconstitution on the skin grafts.

To analyze the cellular composition and molecular changes within the grafts, the researchers utilized:

  • Immunofluorescence Microscopy: To visualize and identify human and mouse cell populations and structural components within the skin grafts.
  • Flow Cytometry (FACS): To quantify and characterize immune cell subsets in peripheral blood and digested skin grafts.
  • Single-cell RNA sequencing (scRNA-Seq): To comprehensively analyze gene expression profiles of individual cells within the skin grafts, allowing for the identification of cell types and their functional states.
  • DAseq (Differentially Abundant Cell Subpopulations): A computational method used in conjunction with scRNA-Seq to identify cell subpopulations whose abundance differs between experimental conditions.
  • In vitro cell culture experiments: Primary human fibroblasts were cultured and treated with various cytokines and signaling molecules to investigate the role of IL-6 trans-signaling in driving fibrotic gene expression.

Datasets

The study utilized the following datasets:

  • Human Skin Grafts: Both healthy donor skin and skin from a patient with pansclerotic morphea (a severe form of localized scleroderma) were used.
  • Human Hematopoietic Stem Cells (HSCs): Obtained from healthy donors for engraftment into the MISTRG6 mice.
  • Peripheral Blood Mononuclear Cells (PBMCs): From deidentified healthy donors for in vitro experiments with CD4+ T cells.
  • Primary Human Fibroblasts: Including foreskin fibroblasts (HFF), normal adult dermal fibroblasts (NDF), and scleroderma skin fibroblasts (SSc) from patients with varying disease durations.

The scRNA-Seq data generated in this study has been deposited in the NCBI Gene Expression Omnibus under the accession number GSE240009.

Key Insights and Ideas

  • MISTRG6 mice as a robust scleroderma model: The study successfully demonstrates that MISTRG6 mice can host human skin grafts and develop a human-like immune system, making them a valuable platform for studying human fibrotic diseases like scleroderma.
  • HSCs mitigate fibrosis by downregulating IL-6: A crucial finding is that engraftment with healthy human HSCs significantly reduced fibrotic signatures in scleroderma skin grafts. This improvement was strongly correlated with a downregulation of human IL-6 expression by mesenchymal cells.
  • Fibroblast depletion in scleroderma grafts: Interestingly, scleroderma skin grafts showed a depletion of human fibroblasts, which were replaced by mouse fibroblasts. This suggests a complex interplay where the fibrotic environment might lead to the rejection or loss of human mesenchymal cells.
  • IL-6 trans-signaling as a key fibrotic driver: The research strongly implicates IL-6 trans-signaling, mediated by soluble IL-6 receptor (sIL6R) shed from activated T cells and IL-6 produced by mesenchymal cells, as a central mechanism driving extracellular matrix (ECM) gene expression and fibrosis.
  • T cell activation and MHC Class II expression: Activated human CD4+ T cells in the grafts showed increased expression of MHC Class II molecules, a marker of T cell activation, but this activation was dampened in HSC-engrafted mice, suggesting a regulatory role of HSCs.

Key Results

  • Successful engraftment: MISTRG6 mice readily accepted human skin grafts and HSCs, developing a diverse human immune cell repertoire.
  • Fibrosis reduction with HSCs: HSC engraftment led to a significant alleviation of fibrosis markers, including reduced expression of collagen and interferon genes, and decreased T cell activation.
  • IL-6 downregulation: Fibrosis improvement correlated with reduced expression of human IL-6 by mesenchymal cells in HSC-engrafted mice.
  • IL-6 trans-signaling drives ECM: In vitro studies confirmed that IL-6 trans-signaling, particularly when driven by sIL6R from activated T cells, significantly induced the expression of profibrotic genes like TNC and COL1A1 in fibroblasts.
  • MHC Class II modulation: Human T cells in scleroderma skin grafts showed altered MHC Class II expression, with decreased expression in HSC-engrafted mice, suggesting reduced T cell activation.

Limitations and Future Work

  • Single scleroderma donor: The study utilized skin from a single patient with pansclerotic morphea. While this allowed for a detailed analysis, future studies should include skin from multiple patients with different subtypes of scleroderma to assess the generalizability of the findings.
  • Human fibroblast depletion: The unexpected depletion of human fibroblasts from scleroderma skin grafts limited the direct analysis of human immune-mesenchymal signaling within the grafts. Future research should aim to identify strategies to maintain human fibroblasts in these models.
  • Species-specific interactions: While the model aims to recapitulate human disease, the replacement of human fibroblasts with mouse fibroblasts introduces a degree of species-specific interaction that warrants further investigation.
  • Mechanisms of IL-6 regulation: The precise mechanisms by which healthy bone marrow-derived immune cells downregulate IL-6 expression in scleroderma skin grafts remain to be fully elucidated. Future work could focus on identifying specific immune cell populations or signaling pathways responsible for this regulation.
  • Therapeutic potential: The findings suggest that targeting IL-6 trans-signaling could be a promising therapeutic avenue for scleroderma. Further studies could explore the efficacy of IL-6 pathway inhibitors in this humanized mouse model.

Summary updated

Abstract

Fibrosis is regulated by interactions between immune and mesenchymal cells. However, the capacity of cell types to modulate human fibrosis pathology is poorly understood due to lack of a fully humanized model system. MISTRG6 mice were engineered by homologous mouse/human gene replacement to develop an immune system like humans when engrafted with human hematopoietic stem cells (HSCs). We utilized MISTRG6 mice to model scleroderma by transplantation of healthy or scleroderma skin from a patient with pansclerotic morphea to humanized mice engrafted with unmatched allogeneic HSC. We identified that scleroderma skin grafts contained both skin and bone marrow-derived human CD4 and CD8 T cells along with human endothelial cells and pericytes. Unlike healthy skin, fibroblasts in scleroderma skin were depleted and replaced by mouse fibroblasts. Furthermore, HSC engraftment alleviated multiple signatures of fibrosis, including expression of collagen and interferon genes, and proliferation and activation of human T cells. Fibrosis improvement correlated with reduced markers of T cell activation and expression of human IL-6 by mesenchymal cells. Mechanistic studies supported a model whereby IL-6 trans-signaling driven by CD4 T cell-derived soluble IL-6 receptor complexed with fibroblast-derived IL-6 promoted excess extracellular matrix gene expression. Thus, MISTRG6 mice transplanted with scleroderma skin demonstrated multiple fibrotic responses centered around human IL-6 signaling, which was improved by the presence of healthy bone marrow-derived immune cells. Our results highlight the importance of IL-6 trans-signaling in pathogenesis of scleroderma and the ability of healthy bone marrow-derived immune cells to mitigate disease.
BibTeX
@inproceedings{odell2023il,
  author = {Ian D. Odell and Kriti Agrawal and Esen Sefik and A.V. Odell and Elizabeth Caves and Nancy C. Kirkiles-Smith and Valerie Horsley and Monique Hinchcliff and Jordan S. Pober and Yuval Kluger and Richard A. Flavell},
  title = {{IL-6 trans-signaling in a humanized mouse model of scleroderma}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2306965120},
}
Figure